Identification of natural compounds as SARS-CoV-2 inhibitors via molecular docking and molecular dynamic simulation

Background Base mutations increase the contagiousness and transmissibility of the Delta and Lambda strains and lead to the severity of the COVID-19 pandemic. Molecular docking and molecular dynamics (MD) simulations are frequently used for drug discovery and relocation. Small molecular compounds from Chinese herbs have an inhibitory effect on the virus. Therefore, this study used computational simulations to investigate the effects of small molecular compounds on the spike (S) protein and the binding between them and angiotensin-converting enzyme 2 (ACE2) receptors. Methods In this study, molecular docking, MD simulation, and protein–protein analysis were used to explore the medicinal target inhibition of Chinese herbal medicinal plant chemicals on SARS-CoV-2. 12,978 phytochemicals were screened against S proteins of SARS-CoV-2 Lambda and Delta mutants. Results Molecular docking showed that 65.61% and 65.28% of the compounds had the relatively stable binding ability to the S protein of Lambda and Delta mutants (docking score ≤ −6). The top five compounds with binding energy with Lambda and Delta mutants were clematichinenoside AR2 (−9.7), atratoglaucoside,b (−9.5), physalin b (−9.5), atratoglaucoside, a (−9.4), Ochnaflavone (−9.3) and neo-przewaquinone a (−10), Wikstrosin (−9.7), xilingsaponin A (−9.6), ardisianoside G (−9.6), and 23-epi-26-deoxyactein (−9.6), respectively. Four compounds (Casuarictin, Heterophylliin D, Protohypericin, and Glansrin B) could interact with S protein mutation sites of Lambda and Delta mutants, respectively, and MD simulation results showed that four plant chemicals and spike protein have good energy stable complex formation ability. In addition, protein–protein docking was carried out to evaluate the changes in ACE2 binding ability caused by the formation of four plant chemicals and S protein complexes. The analysis showed that the binding of four plant chemicals to the S protein could reduce the stability of the binding to ACE2, thereby reducing the replication ability of the virus. Conclusion To sum up, the study concluded that four phytochemicals (Casuarictin, Heterophylliin D, Protohypericin, and Glansrin B) had significant effects on the binding sites of the SARS-CoV-2 S protein. This study needs further in vitro and in vivo experimental validation of these major phytochemicals to assess their potential anti-SARS-CoV-2. Graphical abstract

[1]  Christopher J. L. Murray,et al.  Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. , 2022, JAMA.

[2]  Q. Pan,et al.  Hypericin blocks the function of HSV-1 alkaline nuclease and suppresses viral replication. , 2022, Journal of ethnopharmacology.

[3]  A. Berghuis,et al.  Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency , 2022, Frontiers in Microbiology.

[4]  B. Balasubramanian,et al.  Evaluation of Clove Phytochemicals as Potential Antiviral Drug Candidates Targeting SARS-CoV-2 Main Protease: Computational Docking, Molecular Dynamics Simulation, and Pharmacokinetic Profiling , 2022, Frontiers in Molecular Biosciences.

[5]  J. Dushoff,et al.  Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa , 2022, Science.

[6]  K. Balawender,et al.  Does SARS-CoV-2 affect male urogenital system? , 2022, Current pharmaceutical biotechnology.

[7]  S. Bhatt,et al.  Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study , 2022, The Lancet.

[8]  Benjamin Bowe,et al.  Long-term cardiovascular outcomes of COVID-19 , 2022, Nature Medicine.

[9]  K. Almes,et al.  Molecular detection of SARS-CoV-2 strains and differentiation of Delta variant strains. , 2021, Transboundary and emerging diseases.

[10]  J. Zahradník,et al.  The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance , 2021, Cell Reports.

[11]  Marek J. Łos,et al.  An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment , 2021, Drug Resistance Updates.

[12]  Yeqing Sun,et al.  Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination , 2021, Emerging microbes & infections.

[13]  Xilong Deng,et al.  Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China , 2021, EClinicalMedicine.

[14]  Yudong Ren,et al.  Hypericin Inhibit Alpha-Coronavirus Replication by Targeting 3CL Protease , 2021, Viruses.

[15]  P. Romero,et al.  The Emergence of Sars-CoV-2 Variant Lambda (C.37) in South America , 2021, medRxiv.

[16]  Martin E. Garcia,et al.  The SARS-CoV-2 spike protein is vulnerable to moderate electric fields , 2021, Nature Communications.

[17]  R. Zarnegar,et al.  Neurological manifestations as primary presentation of COVID‐19 in hospitalized patients , 2021, Acta neurologica Scandinavica.

[18]  Kai Li,et al.  ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Infection in COVID-19 Patients , 2021, Frontiers in Medicine.

[19]  W. Cho,et al.  An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies , 2020, Expert review of anti-infective therapy.

[20]  Haiyong Peng,et al.  SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity , 2020, Nature Communications.

[21]  J. Borgio,et al.  Emerging of composition variations of SARS-CoV-2 spike protein and human ACE2 contribute to the level of infection: in silico approaches , 2020, Journal of biomolecular structure & dynamics.

[22]  J. Davie,et al.  Epigenetic regulation of ACE2, the receptor of the SARS-CoV-2 virus. , 2020, Genome.

[23]  P. Rocchi,et al.  Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting , 2020, Molecular Cell.

[24]  A. Schmidtchen,et al.  SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity , 2020, bioRxiv.

[25]  Arumugam Priya,et al.  Ethnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: using structure-based drug discovery approach , 2020, Journal of biomolecular structure & dynamics.

[26]  A. Singh,et al.  Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies , 2020, Journal of biomolecular structure & dynamics.

[27]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[28]  Mohammad Madjid,et al.  Potential Effects of Coronaviruses on the Cardiovascular System: A Review. , 2020, JAMA cardiology.

[29]  Li Xiaobo,et al.  Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) , 2020, Pharmacological Research.

[30]  J. Patel,et al.  COVID-19 and the liver: little cause for concern , 2020, The Lancet Gastroenterology & Hepatology.

[31]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[32]  Ai-Hua Zhang,et al.  Traditional Chinese medicine for COVID-19 treatment , 2020, Pharmacological Research.

[33]  Hyun Pyo Kim,et al.  Therapeutic Potential of the Rhizomes of Anemarrhena asphodeloides and Timosaponin A-III in an Animal Model of Lipopolysaccharide-Induced Lung Inflammation , 2018, Biomolecules & therapeutics.

[34]  S. Sung,et al.  Anti‐inflammatory activity of mulberrofuran K isolated from the bark of Morus bombycis , 2018, International immunopharmacology.

[35]  Sheng-Yong Yang,et al.  Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era , 2016, Briefings Bioinform..

[36]  S. Piazza,et al.  Strawberry tannins inhibit IL-8 secretion in a cell model of gastric inflammation. , 2016, Pharmacological research.

[37]  J. Eloff,et al.  Ochnaflavone and Ochnaflavone 7-O-Methyl Ether two Antibacterial Biflavonoids from Ochna pretoriensis (Ochnaceae) , 2012, Natural product communications.

[38]  T. Huang,et al.  Antihepatitis B Virus Constituents of Solanum Erianthum , 2012 .

[39]  Y. Matsuura,et al.  Tellimagrandin I, HCV invasion inhibitor from Rosae Rugosae Flos. , 2010, Bioorganic & medicinal chemistry letters.

[40]  Yoshitaka Shimotai,et al.  Anti-influenza virus principles from Muehlenbeckia hastulata , 2010, Journal of Natural Medicines.

[41]  Ke Chen,et al.  Investigation of Atomic Level Patterns in Protein—Small Ligand Interactions , 2009, PloS one.

[42]  J. Thornton,et al.  Stereochemical quality of protein structure coordinates , 1992, Proteins.

[43]  Y. Cheng,et al.  Anti-aids agents, 6. Salaspermic acid, an anti-HIV principle from Tripterygium wilfordii, and the structure-activity correlation with its related compounds. , 1992, Journal of natural products.

[44]  D. Barnard,et al.  Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus. , 1992, Antiviral research.